leadf
logo-loader
LSE:OKYO FRA:OK1 OTCQB:EMMLF

Okyo Pharma Ltd

Receive alerts
Market:
LSE
Market Cap:
£41.25 m
Price
4.25 GBX
Change
-2.86%
52 weeks high
13.50
52 weeks low
4.00

In brief

OKYO Pharma Ltd is a biopharmaceutical company developing next-generation therapeutics to improve the lives of patients with inflammatory eye diseases and ocular pain.

The company's goal is to develop first in class drug candidates that prevent the disease instead of controlling it, and it achieves this through our collaboration with pioneer scientists in the field.

Snapshot

  • OKYO Pharma has two main products both targeting key cell receptors
  • Leading product in development treats dry eye syndrome
  • Second candidate is a potential non-opioid analgesic for treating chronic pain

Insight Widest with the analysis, Proactive gives perspectives that others don't.

Are small-cap biotech stocks good investments now?

We look at the sector's success stories and assess what we can expect in the coming months

on 14/8/20